Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.02, 5.03, 9.01 · 8-K

Henry Schein, Inc.

HSICNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive Leadership Changes On January 10, 2026, the Board of Directors (the “Board”) of Henry Schein, Inc. (the “Company”) appointed Mr. Frederick Lowery as Chief Executive Officer of the Company, effective March 2, 2026 (the “Effective Date”).…

Filed Jan 12, 2026Accepted Jan 12, 2026, 7:00 AM ESTCIK 1000228Accession 0001193125-26-009725
Share

Company context

Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Current securities

Recent company filings

  1. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 22, 2026
  2. 144 filingAug 14, 2026
  3. 10-Q filingAug 4, 2026
  4. Results of Operations and Financial ConditionAug 4, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 30, 2026

Disclosure sections

Items 5.02, 5.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive Leadership Changes On January 10, 2026, the Board of Directors (the “Board”) of Henry Schein, Inc. (the “Company”) appointed Mr. Frederick Lowery as Chief Executive Officer of the Company, effective March 2, 2026 (the “Effective Date”). In connection with Mr. Lowery’s appointment, the Board expanded the size of the Board from 14 to 15 members and appointed Mr. Lowery to fill the resulting vacancy, in each case, effective as of the Effective Date. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc. in 2005 as head of operations for the Molecular BioProducts business of Fisher Scientific International. As previously announced, the Company had entered into a letter agreement with its current Chief Executive Officer, Mr. Stanely M. Bergman, pursuant to which he had agreed to extend his employment for a term through the earlier of (a) the date of commencement of employment of a new Chief Executive Officer of the Company and (b) the date following the thirtieth (30th) day after Mr. Bergman notifies the Company in writing of his decision to end his employment with the Company. Accordingly, Mr. Bergman will continue as Chief Executive Officer of the Company until the date that Mr. Lowery commences employment with the Company, and then following his retirement as Chief Executive Officer Mr. Bergman will continue as Chairman of the Board. The Company issued a press release on January 12, 2026 announcing Mr. Lowery’s appointment, a copy of which is attached as Exhibit 99.1 hereto. Employment Agreement with Mr. Lowery In connection with his appointment, Mr. Lowery and the Company entered into an employment agreement, dated January 10, 2026 (“Employment Agreement”). Under the Employment Agreement, Mr. Lowery will receive during the employment period an annual base salary of $1,250,000 and a target annual bonus opportunity under the Company’s Incentive Plan of no less than 150% of base salary, subject to the attainment of performance criteria established by the Compensation Committee of the Board (the “Compensation Committee”). The performance criteria for 2026 will be 70% based on the Company’s earnings per share and 30% based on the Company’s strategic scorecard results (with a maximum payment of 175% of target). The annual bonus payout for fiscal year 2026 will equal no less than $1,875,000. The Employment Agreement provides that Mr. Lowery will be eligible to receive annual equity awards under the Company’s 2024 Stock Incentive Plan (or successor plan). Solely with respect to the equity awards to be granted to Mr. Lowery in fiscal year 2026, such equity awards will have an aggregate target grant date fair value equal to $10,000,000, allocated as follows: (i) 50% in the form of stock options, which will vest ratably on each of the first four anniversaries of the grant date; (ii) 25% in the form of time-based restricted stock units, which will vest ratably on each of the first four anniversaries of the grant date; and (iii) 25% in the form of performance-based restricted stock units, which will vest on the third anniversary of the grant date subject to the achievement and certification of performance goals. All vesting is subject to Mr. Lowery’s continued employment through the applicable vesting dates, except in the case of certain termination events. In addition, Mr. Lowery will be eligible to be reimbursed for all reasonable expenses associated with Mr. Lowery’s relocation in connection with his employment with the Company, up to $500,000, subject to customary submission of appropriate documentation evidencing such expenses. The Employment Agreement further provides that, subject to Mr. Lowery not receiving an annual bonus paid in 2026 and remaining employed by the Company through the date of payment, he will receive a one-time bonus in the amount of $1,184,000 on or as soon as reasonably practicable following the Effective Date. In addition, Mr. Lowery will also automatically receive, on the Effective Date, a special one-time equity award with a target value of $2,500,000 (the “Sign-On Award”). The Sign-On Award will be comprised of time-based restricted stock units, which will be issued pursuant to a Restricted Stock Unit Agreement to be entered into on Mr. Lowery’s start date and will vest ratably on each of the first three anniversaries of the grant date, subject to Mr. Lowery’s continued employment through the applicable vesting dates. If Mr. Lowery is terminated by the Company without cause, resigns for good reason, dies or becomes disabled the then-unvested portion of the Sign-On Award will vest in full. Subject to Mr. Lowery’s timely execution and non-revocation of a release of claims in a form reasonably satisfactory to the Company, Mr. Lowery will be eligible to receive the benefits provided by the amended and restated Henry Schein, Inc. Executive Severance Plan (the “Executive Severance Plan”) or the Company’s Executive Change in Control Plan, as applicable, which for a Chief Executive Officer generally provide, upon a qualifying termination not in connection with a change in control, for a pro-rated annual bonus for the year of termination based on actual performance, cash severance equal to two times the sum of base salary and the average annual bonus paid over the three fiscal years preceding termination, payable in installments over the two-year period following such termination, pro rata acceleration of equity awards (subject to actual performance for performance-based awards), subsidized COBRA health coverage, and outplacement services (collectively, the “Non-CIC Severance Benefits”), and, in the case of a qualifying termination in connection with a change in control, for severance pay equal to 2.5 times base salary and target bonus, payable in one lump sum, pro rata annual incentive compensation for the year of termination based on actual performance, accelerated vesting of equity and certain retirement benefits, and continued health and welfare benefits, in each case subject to the terms of the Employment Agreement and the applicable plan. With respect to a qualifying termination not in connection with a change in control, the Employment Agreement further provides Mr. Lowery protection against amendments to the Company’s Executive Severance Plan that would materially and adversely affect his rights under such plan without his prior written consent. The foregoing descriptions of the Employment Agreement and the Sign-On Award do not purport to be complete and are qualified in their entirety by reference to the full text of the Employment Agreement, which is attached as Exhibit 10.1 hereto, and the full text of the Sign-On Award Agreement, which is attached as Exhibit 10.2 hereto, and are incorporated by reference herein. No arrangement or understanding exists between Mr. Lowery and any other person pursuant to which Mr. Lowery was selected to serve as Chief Executive Officer. There have been no related party transactions between the Company or any of its subsidiaries and Mr. Lowery reportable under Item 404(a) of Regulation S-K. Mr. Lowery has no family relationships with any of the Company’s directors or executive officers. Executive Severance Plan On January 9, 2026, the Compensation Committee approved the adoption of the Amended and Restated Executive Severance Plan, effective March 2, 2026. The Amended and Restated Executive Severance Plan generally continues the existing provisions of the plan and incorporates the following change: the Chief Executive Officer, who is currently excluded from participation, will become eligible to participate and, upon a qualifying termination not in connection with a change in control, will be entitled to receive the Non-CIC Severance Benefits. The foregoing summary of the Amended and Restated Executive Severance Plan does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Executive Severance Plan, which is attached as Exhibit 10.3 hereto and incorporated herein by reference.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On January 10, 2026, upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved an amendment and restatement of the Company’s Fourth Amended and Restated By-Laws (as amended and restated, the “By-Laws”), effective immediately. Among other things, the amendments: eliminate the requirement that the Board appoint a President and related concepts; and permit the Board to appoint a Chief Executive Officer who is not also President or Chairman of the Board. The foregoing summary of the amendments to the By-Laws does not purport to be a complete description and is qualified in its entirety by reference to the full text of the By-Laws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) d52378dex991.htm

EX-99.1 6 d52378dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Henry Schein Names Frederick M. Lowery as Chief Executive Officer Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence MELVILLE, N.Y., January 12, 2026 - Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer (“CEO”), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. Mr. Lowery brings more than two decades of healthcare expertise to Henry Schein, with a strong track record of scaling complex businesses to drive significant growth and sustained value creation. Most recently, he served as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher Scientific (NYSE: TMO), leading the Fisher Scientific distribution channel’s above-market performance. His exp…

Open exhibit ↗